Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates

Company Performance - Day One Biopharmaceuticals reported a quarterly loss of $0.35 per share, better than the Zacks Consensus Estimate of a loss of $0.46, and an improvement from a loss of $0.72 per share a year ago, representing an earnings surprise of 23.91% [1] - The company posted revenues of $30.76 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 4.90%, compared to zero revenues a year ago [2] - The stock has lost about 41% since the beginning of the year, while the S&P 500 has declined by 3.9% [3] Earnings Outlook - The current consensus EPS estimate for the coming quarter is -$0.44 on revenues of $34.88 million, and for the current fiscal year, it is -$1.67 on revenues of $149.97 million [7] - The estimate revisions trend for Day One Biopharmaceuticals is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Day One Biopharmaceuticals belongs, is currently in the top 31% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]